UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 178

Sortiert nach

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

Annals of the rheumatic diseases, 2010-03, Vol.69 (3), p.522-528

2010

Volltextzugriff (PDF)

Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register

Rheumatology (Oxford, England), 2006-12, Vol.45 (12), p.1558-1565

2006

Volltextzugriff (PDF)

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2011-10, Vol.70 (10), p.1810-1814

2011

Volltextzugriff (PDF)

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2010-06, Vol.69 (6), p.1086-1091

2010

Volltextzugriff (PDF)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2009-02, Vol.68 (2), p.209-215

2009

Volltextzugriff (PDF)

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

Annals of the rheumatic diseases, 2004-12, Vol.63 (12), p.1538-1543

2004

Volltextzugriff (PDF)

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug

Rheumatology (Oxford, England), 2008-07, Vol.47 (7), p.1000-1005

2008

Volltextzugriff (PDF)

Biologic therapies and pregnancy: the story so far

Rheumatology (Oxford, England), 2014-08, Vol.53 (8), p.1377-1385

2014

Volltextzugriff (PDF)

The British Society for Rheumatology Biologics Register: 6 years on

Rheumatology (Oxford, England), 2008-10, Vol.47 (10), p.1441-1443

2008

Volltextzugriff (PDF)

Assessing the safety of new drugs during pregnancy

British journal of dermatology (1951), 2018-01, Vol.178 (1), p.18-19

Hyrich, K.L.

2018

Volltextzugriff (PDF)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

Rheumatology (Oxford, England), 2010-04, Vol.49 (4), p.697-705

2010

Volltextzugriff (PDF)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

Annals of the rheumatic diseases, 2009-01, Vol.68 (1), p.69-74

2009

Volltextzugriff (PDF)

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

Arthritis care & research (2010), 2010-06, Vol.62 (6), p.755-763

2010

Volltextzugriff (PDF)

The Role of Anti–Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?

Seminars in oncology, 2010-02, Vol.37 (1), p.11-19

2010

Volltextzugriff (PDF)

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

Arthritis and rheumatism, 2006-08, Vol.54 (8), p.2368-2376

2006

Volltextzugriff (PDF)

FRI0157 The eular study group for biologic registers: initiating a combined approach to the analysis of rare outcomes

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A423-A424

2013

Volltextzugriff (PDF)

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

Rheumatology (Oxford, England), 2015-06, Vol.54 (6), p.1074-1079

2015

Volltextzugriff (PDF)

Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety

Annals of the Rheumatic Diseases, 2004-12, Vol.63 (12), p.1538-1543

Hyrich, K L

2004

Volltextzugriff (PDF)

OP0065 Quantifying the Economic Impact of Serious Infections from Anti-TNFS for Rheumatoid Arthritis: Results from the BSRBR-RA

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A72-A72

2013

Volltextzugriff (PDF)

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

Arthritis and rheumatism, 2007-09, Vol.56 (9), p.2905-2912

2007

Volltextzugriff (PDF)

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

The pharmacogenomics journal, 2014-04, Vol.14 (2), p.171-175

2014

Volltextzugriff (PDF)

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

Rheumatology (Oxford, England), 2011-01, Vol.50 (1), p.124-131

2011

Volltextzugriff (PDF)

AB0289 Can cd11c expression successfully predict response to etanercept in rheumatoid arthritis patients?

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A875-A875

2013

Volltextzugriff (PDF)

Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies

Arthritis and rheumatism, 2007-09, Vol.56 (9), p.2896-2904

2007

Volltextzugriff (PDF)

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

Rheumatology (Oxford, England), 2013-01, Vol.52 (1), p.91-98

2013

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(84)
Rheumatology
(79)
Humans
(78)
Arthritis, Rheumatoid - Drug Therapy
(52)
Rheumatoid Arthritis
(51)
Female
(50)
Male
(48)
Middle Aged
(45)
Antirheumatic Agents - Therapeutic Use
(43)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(40)
Aged
(34)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Diseases Of The Osteoarticular System
(33)
Adult
(29)
Inflammatory Joint Diseases
(29)
Antirheumatic Agents - Adverse Effects
(24)
Registries
(24)
Tumor Necrosis Factor-Tnf
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug

Biologic therapies and pregnancy: the story so far

The British Society for Rheumatology Biologics Register: 6 years on

Assessing the safety of new drugs during pregnancy

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

The Role of Anti–Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

FRI0157 The eular study group for biologic registers: initiating a combined approach to the analysis of rare outcomes

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety

OP0065 Quantifying the Economic Impact of Serious Infections from Anti-TNFS for Rheumatoid Arthritis: Results from the BSRBR-RA

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

AB0289 Can cd11c expression successfully predict response to etanercept in rheumatoid arthritis patients?

Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

Suchergebnisse filtern